Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Necrotizing Enterocolitis Market to Register Stunning Growth at a CAGR of 26% During the Forecast Period (2026–2036) | DelveInsight

globenewswire.com
JAGX Jaguar Health is mentioned indirectly as the parent company of Napo Therapeutics, which is developing therapies for Short Bowel Syndrome. The article does not provide specific sentiment or details regarding Jaguar Health's direct involvement or performance. MRK Merck KGaA is mentioned as a key company in the Hypoxia market. The article does not provide specific sentiment or details regarding Merck KGaA's current performance or outlook related to this market. CASI CASI Pharmaceuticals is mentioned as a key company in the Hypoxia market. The article does not provide specific sentiment or details regarding CASI Pharmaceuticals' current performance or outlook related to this market. JAZZ Jazz Pharma is mentioned as a key company in the Hypoxic Ischemic Encephalopathy market. The article does not provide specific sentiment or details regarding Jazz Pharma's current performance or outlook related to this market.

Necrotizing Enterocolitis Market to Register Stunning Growth at a CAGR of 26% During the Forecast Period (2026–2036) | DelveInsight New York, USA, July 27, 2026 (GLOBE NEWSWIRE) -- Necrotizing Enterocolitis Market to Register Stunning Growth at a CAGR of 26% During the Forecast Period (2026–2036) | DelveInsight

The necrotizing enterocolitis market is witnessing steady growth, primarily driven by the increasing incidence of preterm births worldwide, as premature infants are at the highest risk of developing NEC. Rising awareness among healthcare providers regarding early diagnosis and preventive care is further supporting market expansion. Additionally, ongoing research activities focused on novel therapeutics such as IBP-9414 (Infant Bacterial Therapeutics), STMC-106 (Siolta Therapeutics), ST266 (Noveome Biotherapeutics), Protego-PD (Plakous Therapeutics), and others, probiotics, stem cell therapies, and targeted interventions are creating significant growth opportunities.

Recently published Necrotizing Enterocolitis Market Insights report includes a comprehensive understanding of current treatment practices, necrotizing enterocolitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Necrotizing Enterocolitis Market Summary

Discover necrotizing enterocolitis market growth opportunities @ https://www.delveinsight.com/report-store/necrotizing-enterocolitis-market

Key Factors Driving the Growth of the Necrotizing Enterocolitis Market

Aparna Thakur, project manager of forecasting at DelveInsight, said that the pipeline candidate IBP-9414 is expected to follow a moderate uptake trajectory, reflecting its investigational status and gradual adoption as clinical evidence emerges. Meanwhile, STP206 is anticipated to show gradual uptake.

Necrotizing Enterocolitis Market Analysis

Learn more about disease-modifying therapies for necrotizing enterocolitis @ Necrotizing Enterocolitis Treatment Market

Necrotizing Enterocolitis Competitive Landscape

Some of the necrotizing enterocolitis drugs under development include IBP-9414 (Infant Bacterial Therapeutics), STMC-106 (Siolta Therapeutics), ST266 (Noveome Biotherapeutics), Protego-PD (Plakous Therapeutics), and others.

IBT is advancing IBP-9414, a probiotic-based therapeutic candidate designed to become the first approved treatment of its kind for preventing severe complications in premature infants, including necrotizing enterocolitis (NEC) and sepsis. The therapy aims to support healthy gastrointestinal development in preterm newborns. IBP-9414 contains Lactobacillus reuteri, a naturally occurring bacterial strain found in human breast milk that exhibits anti-inflammatory and antimicrobial properties while promoting intestinal motility and maturation of the gut lining. The candidate is currently being evaluated in a registration-enabling pivotal Phase III trial for NEC prevention. IBT anticipates filing for regulatory approval in 2026, and findings from its Phase III "Connection Study" involving very low birth weight infants have been published in the journal Pediatric Research.

Siolta Therapeutics is developing STMC-106, a microbiome-based live biotherapeutic candidate within its broader microbial therapeutics portfolio. The program is aimed at preventing and treating necrotizing enterocolitis in preterm infants through targeted modulation of the gut microbiome to enhance intestinal health and lower disease susceptibility. STMC-106 remains in the preclinical stage of development and has secured grant funding to support ongoing research activities as the company works toward future clinical testing.

The anticipated launch of these emerging necrotizing enterocolitis therapies are poised to transform the necrotizing enterocolitis market landscape in the coming years. As these cutting-edge necrotizing enterocolitis therapies continue to mature and gain regulatory approval, they are expected to reshape the necrotizing enterocolitis market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

To know more about emerging necrotizing enterocolitis therapies, visit @ Necrotizing Enterocolitis Medication

Recent Developments in the Necrotizing Enterocolitis Market

What is Necrotizing Enterocolitis?

Necrotizing enterocolitis is a serious and potentially life-threatening gastrointestinal disease that primarily affects premature and very low birth weight infants. The condition is characterized by inflammation and necrosis of the intestinal wall, which can lead to intestinal perforation, severe infection, sepsis, and even death. Although the exact cause of NEC remains unclear, it is believed to result from a combination of intestinal immaturity, abnormal bacterial colonization, impaired blood flow to the gut, and an exaggerated inflammatory response. NEC typically develops within the first few weeks of life and presents with symptoms such as feeding intolerance, abdominal distension, vomiting, bloody stools, and lethargy. Despite advances in neonatal care, NEC remains one of the most devastating complications in neonatal intensive care units (NICUs), highlighting the need for improved preventive and therapeutic strategies.

Necrotizing Enterocolitis Epidemiology Segmentation

The necrotizing enterocolitis epidemiology section provides insights into the historical and current necrotizing enterocolitis patient pool and forecasted trends for the leading markets. Across the 7MM, the population of preterm infants with birth weight ≤1,500 g is expected to remain stable to slightly increase through 2030, largely due to improved neonatal survival rates rather than a significant rise in preterm birth incidence.

The necrotizing enterocolitis market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets segmented into:

Download the report to understand the future of necrotizing enterocolitis treatment @ Necrotizing Enterocolitis Treatment Options

Scope of the Necrotizing Enterocolitis Market Report

Discover more about next-generation necrotizing enterocolitis drugs @ Necrotizing Enterocolitis Clinical Trials

Table of Contents

Related Reports

Necrotizing Enterocolitis Clinical Trial Analysis

Necrotizing Enterocolitis Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key necrotizing enterocolitis companies, including Infant Bacterial Therapeutics, Noveome Biotherapeutics, Siolta Therapeutics, and others.

Short Bowel Syndrome Market

Short Bowel Syndrome Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key SBS companies including Takeda, Ironwood Pharmaceuticals (VectivBio), Zealand Pharma, Hanmi Pharmaceutical, Napo Therapeutics (family company of Jaguar Health), and others.

Short Bowel Syndrome Clinical Trial Analysis

Short Bowel Syndrome Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key SBS companies, including VectivBio, Zealand Pharma, 9 Meters Biopharma, Hanmi Pharmaceutical, Adocia, PhaseBio Pharmaceuticals, Surrozen, NorthSea Therapeutics, and others.

Hypoxia Market

Hypoxia Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key hypoxia companies, including NuvOx Pharma, Bioxytran, Stream Biomedical, Merck KGaA, F. Hoffmann-La Roche, Aileron Therapeutics, CASI Pharmaceuticals, and others.

Hypoxic Ischemic Encephalopathy Market

Hypoxic Ischemic Encephalopathy Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key hypoxic ischemic encephalopathy companies, including ReAlta Life Sciences, JCR Pharma, Jazz Pharma, Hope Biosciences, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.